GMED - GenoMed Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical GMED - GenoMed Inc.

Previous 10 Next 10

From: jmhollen	10/13/2005 10:08:32 AM
	of 347

GenoMed Offers Trial for Influenza and Avian Influenza Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com ST. LOUIS--October 13, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that it has begun Internet-based clinical trials for influenza and avian influenza, since the same treatment approach is expected to work for both kinds of virus. There is currently no reliable vaccine or treatment for avian influenza. There are antiviral drugs and a vaccine for regular influenza, but they're far from perfect. The yearly influenza vaccine was recently reported to work in only a third of patients. GenoMed's treatment has been 80% effective in a limited number of patients with West Nile virus encephalitis since 2003. The company is now ready to test it in viral pneumonias. Any one interested in signing up for GenoMed's clinical trial just needs to go to GenoMed's website (www.genomed.com), and then click on "Company News" followed by "Investor Relations/Press Releases" followed by "Presentations" (in the upper right-hand corner). The trial documents are self-explanatory. About GenoMed GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). .

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: jmhollen who wrote (283)	10/13/2005 11:25:53 AM
From: Tadsamillionaire	of 347

Deadly Asian bird flu reaches fringes of Europe Reuters - 2 hours, 36 minutes ago BRUSSELS - A strain of bird flu that can be deadly for humans has spread from Asia to the fringes of Europe, the European Commission said on Thursday, warning countries to prepare for a potential pandemic. EU Health and Consumer Protection chief Markos Kyprianou said a strain of bird flu found in Turkey had been identified as the same H5N1 virus that killed more than 60 people in Asia since 2003 and forced the slaughter of millions of birds. news.yahoo.com

Share	RecommendKeepReply Mark as Last Read

From: Tadsamillionaire	10/18/2005 3:20:10 PM
	of 347

GMED mentioned with the big boys, >>The technology for producing a vaccine exists, but manufacturers will probably have to wait until the exact pandemic strain is known before they can build a vaccine to fight it. Currently, a few companies like GlaxoSmithKline, Chiron, Sanofi Pasteur and GenoMed are working on it, but it will take up to six months for a vaccine to be produced in great volume. Even then, it will be just a fraction of the amount needed globally.<< Production of vaccine in bulk may take 6 mths JEETHA D?€™SILVA AND CHHAVI DANG TIMES NEWS NETWORK[ SATURDAY, OCTOBER 15, 2005 12:59:08 AM] NRI Special Offer! MUMBAI: As the threat of bird flu hovers over India, it is apparent that some drastic action is needed as the flu vaccine is falling appallingly short. What complicates the situation is that the next pandemic may be caused by a new strain of the influenza virus. The 60 deaths that have been reported so far are those that have been due to the H5N1 strain that causes avian influenza. At present, there is no specific vaccine to prevent avian influenza in human beings. The technology for producing a vaccine exists, but manufacturers will probably have to wait until the exact pandemic strain is known before they can build a vaccine to fight it. Currently, a few companies like GlaxoSmithKline, Chiron, Sanofi Pasteur and GenoMed are working on it, but it will take up to six months for a vaccine to be produced in great volume. Even then, it will be just a fraction of the amount needed globally. Oseltamivir, sold by global pharma major Roche under the brand name Tamiflu, is the most effective drug for the prevention and treatment of human influenza. This drug is not available in the country, though sources say that the company plans to launch the product in India shortly. One of the early measures many governments are adopting to check the spread of the virus is surveillance of poultry and migratory birds. The department of animal husbandry claims that it has been conducting surveillance checks for the last four years, not only on domestic birds but also on the migratory birds. Poultry sales have so far not been affected. A distributor for a leading poultry firm told ET that chicken sales have not shown any signs of falling. “No evidence of avian influenza has been found in poultry or migratory birds,” said Santanu Kumar Bandyopadhyay, commissioner, animal husbandry department. economictimes.indiatimes.com TAKEN FROM RB BOARD.... ragingbull.lycos.com

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Tadsamillionaire who wrote (285)	10/22/2005 4:05:18 AM
From: jmhollen	of 347

I wish the folks at GMED and the folks at NNVC would get together and chat. I'm seeing some valuable synergies here. John :-) .

Share	RecommendKeepReply Mark as Last Read

From: jmhollen	10/25/2005 11:04:55 AM
	of 347

GenoMed CEO Honored for Innovation in Healthcare by St. Louis Business Journal Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com ST. LOUIS--October 25, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its CEO, David W. Moskowitz MD, has been nominated as a finalist in the 2005 Health Care Heroes sponsored by the St. Louis Business Journal. Now in its second year, the Health Care Heroes of St. Louis is an annual celebration organized by the St. Louis Business Journal to tell the stories of those who have benefited from the innovation and dedication of heroes in the health care profession. The event will be held November 10, 2005 in St. Louis (http://stlouis.bizjournals.com/stlouis/event/1916). GenoMed currently earns revenues from its published protocols to reverse chronic kidney failure due to diabetes or high blood pressure, and delay progression of emphysema. These diseases affect 90 million Americans. The Company is currently conducting free trials for many additional diseases, including Parkinson's disease, Alzheimer's disease, most cancers, and viral diseases including West Nile virus encephalitis, regular influenza, and avian influenza. Any one interested in signing up for GenoMed's trial just needs to go to GenoMed's website (www.genomed.com), and follow the links for the "Flu trial." The trial documents are self-explanatory. About GenoMed GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). .

Share	RecommendKeepReply Mark as Last Read

From: jmhollen	11/14/2005 2:02:26 PM
	of 347

"Cytokine Storm" Paper Confirms GenoMed's Approach to Avian Flu Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com ST. LOUIS—November 14, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its approach to avian influenza was confirmed last week by a Hong Kong research group who found that the avian influenza virus induces a "cytokine storm" in human lung cells grown in tissue culture. Dr. J.S.M. Peiris and colleagues published last week in Respiratory Research that avian influenza (H5N1) viruses isolated from dead patients cause lung cells to produce many more pro-inflammatory molecules, called "cytokines," than regular influenza A viral strains. This research confirms GenoMed's hypothesis that the host's immune response to the virus is what causes death, not the replication of the virus itself. About GenoMed GenoMed's broad-spectrum anti-viral approach is specifically mentioned in BioShield II, (see Section 2151 of Senate bill S. 975). GenoMed uses already existing, safe medication present in every drug store and hospital in the world. GenoMed is now charging a one-time license fee of US $10 to access its treatment approach, which is patent-pending globally. Please see www.genomed.com for details. .

Share	RecommendKeepReply Mark as Last Read

From: jmhollen	11/28/2005 7:40:19 PM
	of 347

*GenoMed Considers Offering Low-Cost Health Insurance to America's Uninsured* Contact: David Moskowitz MD CEO, GenoMed, Inc. Tel. 314-983-9933 dwmoskowitz@genomed.com ST. LOUIS, November 28, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, announced today that it is considering partnering to offer a low-cost health insurance product to compete for the uninsured market. By avoiding expensive hospitalizations for diabetes, high blood pressure, and emphysema, GenoMed can already slash healthcare costs for cardiovascular disease. Two-thirds of Americans die from cardiovascular disease, and one third from cancer. With its Healthchip® to serve as an early warning system for the top six common cancers in whites, breast, colon, lung, ovarian, pancreatic, and prostate, GenoMed has taken the first step towards curing cancer. The company wants to pass these savings on to the consumer in the form of markedly lower premiums. Currently, health insurance costs $6,000 a year, but life expectancy from cardiovascular disease and cancer is still poor. GenoMed thinks it can provide better patient outcomes for up to 40% less. The company is currently looking for two other partners to provide low cost health insurance: a mail-order pharmacy to supply drugs inexpensively, and an insurance carrier for catastrophic hospitalization. Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "If hospitalization can be avoided for most patients by judicious use of outpatient medications and tests, then insurance rates can be lowered considerably. Hospitalization will become the exception, not the norm, and catastrophic hospitalization insurance rates should apply. This is the whole promise of medical genomics and preventive molecular medicine." GenoMed hopes to offer an insurance product inexpensive enough to attract America's 45 million uninsured patients. Given the rising cost of healthcare, other payors should soon follow as customers, including employers, state Medicaid programs, Medicare, overseas National Health Services, etc. About GenoMed™ GenoMed is leading the clinical revolution which knowledge of disease genes makes possible. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company plans to increase the scope and predictive power of its Healthchip® by collecting patient samples from additional types of cancer, and additional ethnic groups. The company is finding that its science requires it to also discover new business models.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: jmhollen who wrote (289)	2/9/2006 11:29:19 AM
From: Tadsamillionaire	of 347

GenoMed's Formula for Better Healthcare at Half the Price = GenoMed + President Bush's HSAs Wednesday February 1, 9:30 am ET ST. LOUIS, Feb. 1 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management company, announced today that it can deliver better healthcare for half the cost, if coupled with the President's health savings accounts (HSAs). biz.yahoo.com Thanks to President Bush's HSAs, GenoMed can now offer an insurance plan inexpensive enough to attract most of America's 46 million uninsured patients. Given the high cost of healthcare, other customers should quickly follow, including large employers, state Medicaid programs, Medicare, overseas National Health Services, etc.

Share	RecommendKeepReply Mark as Last Read

From: Tadsamillionaire	2/21/2006 3:46:56 PM
	of 347

GenoMed Trial Results: HIV -- Viral Load Goes to Zero ST. LOUIS, Feb. 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health, announced today that its first HIV patient had his viral load fall to zero after starting GenoMed's trial. The patient is a 54 year old African American man who was diagnosed with HIV 2 years ago. He was being treated with a standard triple-drug 'cocktail' and had a stable viral load when he began GenoMed's trial this past summer, as shown in the following table: Date HIV viral load (copies of the virus per milliliter) 4/11/05 160 6/23/05 228 7/19/05 225 8/29/05 START OF GenoMed's TRIAL 11/2005 0 12/2005 0 1/2006 Switch from Sustiva(R) to Kaletra(R), which had failed this patient in the past 2/14/06 109 Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, 'In this trial, we've been using blood pressure pills, for which we have a 'use' patent that is pending. Why this should work is as interesting as the fact that it has worked. It points out the clinical reliability of the genomic epidemiologic data that we published in 2002.' Continued Dr. Moskowitz, 'Our approach, if it is confirmed in other HIV patients, may help with the chronic treatment of HIV patients. Our earlier data suggests that this approach may also decrease infectivity of the HIV virus in the first place. Because these drugs already are on the shelves in most pharmacies on earth, including Africa, it could be quite helpful in the global struggle against HIV/AIDS.'

Share	RecommendKeepReply Mark as Last Read

From: jmhollen	3/1/2006 1:16:15 PM
	of 347

*GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure* Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com ST. LOUIS—March 1, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, announced today that it received its second patent (US Patent #6,998,404) for the "Treatment or prevention of acute renal failure." Acute kidney failure usually happens when a patient gets dehydrated. Acute kidney failure currently requires a lengthy hospital stay, often involving daily kidney dialysis in the Intensive Care Unit. In addition to the extra cost, acute kidney failure also carries up to a 50% risk of dying. Avoiding dialysis in the first place should greatly improve patient survival and lower healthcare costs. Said David Moskowitz, MD, FACP, GenoMed's CEO and Chief Medical Officer, "Our patented protocol should be of immediate use to every hospital around the world, especially in places without convenient dialysis. It should be especially useful in disaster zones like New Orleans and earthquakes, as well as the battlefield, where people get dehydrated and go into kidney failure, but can't be dialyzed right away." Added Dr. Moskowitz, "In a pilot series, our protocol was safe and effective in a dozen newborns and nine adults, including several patients with combined liver and kidney failure, so-called hepato-renal syndrome. We invite interested physicians to collaborate with us in extending these results to additional patients." About GenoMed GenoMed finds disease-causing genes, and uses this knowledge to devise new treatment strategies. The Company uses already existing medications whenever possible to maximize safety as well as minimize development costs. GenoMed then passes these savings on to healthcare consumers. GenoMed's treatment for acute kidney failure uses an already existing intravenous medication. An oral form may also work, which would be especially useful in natural disasters and the battlefield.

Share	RecommendKeepReply Mark as Last Read